KLOW Blend Research Guide — GHK-Cu + KPV + BPC-157 + TB-500 Quad Peptide Anti-Inflammatory & Tissue Repair Research (2026)
- The KLOW Blend (YPB.264) is a four-component research peptide combination containing GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg), and TB-500 (10mg) in a single lyophilized vial. It is designed as a research tool for studying combined anti-inflammatory, tissue repair, collagen synthesis, and regenerative biology across four complementary but mechanistically non-overlapping peptide pathways simultaneously. All four components are established research-grade synthetic peptides with independent published literature bases. Research Use Only (RUO).
- Component mechanisms: GHK-Cu (glycyl-L-histidyl-L-lysine:copper; copper tripeptide) acts through TGF-β upregulation, VEGF/EGF pathway activation, and direct collagen synthesis promotion; KPV (Lys-Pro-Val; α-MSH C-terminal tripeptide) activates melanocortin receptors (MC1R/MC3R) → NF-κB suppression → anti-inflammatory; BPC-157 (Body Protection Compound-157; 15-AA stable gastric pentadecapeptide) acts through FAK-paxillin pathway, VEGF/NO signaling, and tendon growth factor upregulation; TB-500 (thymosin β4 synthetic analog; 43 AA) sequesters G-actin via LXXLL motif, promotes cell migration, and activates wound healing cascades.
- The KLOW research rationale: each component addresses a different layer of the inflammatory and tissue repair cascade. GHK-Cu targets extracellular matrix (ECM) remodeling and copper-dependent antioxidant systems. KPV targets melanocortin-mediated NF-κB inflammatory signaling. BPC-157 targets vascular and tissue repair growth factor pathways. TB-500 targets cellular migration and actin dynamics. Together, they provide simultaneous coverage of the ECM, immune, vascular, and cytoskeletal dimensions of repair biology. YPB.264. Research Use Only (RUO). Updated April 2026.
- Pricing reference: GHK-Cu 50mg (YPB.221): Premier $23.22 / Core $27.87 / MSRP $80. Download the full catalog for all blend pricing. Individual component guides: GHK-Cu | KPV | BPC-157 | TB-500.
What Is the KLOW Blend and How Does Each Component Contribute?
BPC-157 10mg + TB-500 10mg
Quad-Pathway Anti-Inflammatory Research
The KLOW Blend name encodes its composition: KPV + Lysyl (GHK-Cu) + Overall tissue repair (BPC-157) + Wound healing (TB-500). Updated April 2026. Its research rationale is that inflammation and tissue damage operate through multiple parallel cascades simultaneously — ECM breakdown, cytokine signaling, vascular disruption, and cellular migration impairment all occurring at once. A single-compound research design that targets only one pathway provides an incomplete model of the full repair process. The KLOW Blend provides a single-vial research tool for investigating how these four mechanistically distinct peptides interact, whether they produce additive or synergistic effects on repair endpoints, and which pathways dominate across different tissue or cellular contexts.
All four components are well-characterized individual research peptides available separately in the YPB catalog. The blend is not a proprietary formulation with unique chemistry — it is a research convenience product that combines four established compounds with complementary mechanisms in a single co-lyophilized vial.
Glycyl-L-Histidyl-L-Lysine Copper
Copper tripeptide; ECM remodeling, collagen synthesis, VEGF/EGF upregulation, antioxidant (SOD/catalase), TGF-β1 pathway. See GHK-Cu Research Guide.
Lys-Pro-Val (α-MSH C-Terminal Fragment)
MC1R/MC3R melanocortin receptor agonist; NF-κB suppression; TNF-α/IL-1β/IL-6 inhibition; gut/skin anti-inflammatory. See KPV Research Guide.
Body Protection Compound-157
15-AA stable gastric pentadecapeptide; FAK-paxillin pathway; VEGF/angiogenesis; NO synthase; tendon/ligament repair; GI mucosal healing. See BPC-157 Research Guide.
Thymosin β4 Synthetic Analog
43-AA actin-sequestering peptide; LXXLL motif; G-actin binding; cell migration; wound healing cascades; anti-inflammatory. See TB-500 Research Guide.
Key Blend Characteristics
| Parameter | Value |
|---|---|
| YPB SKU | YPB.264 |
| Composition | GHK-Cu 50mg + KPV 10mg + BPC-157 10mg + TB-500 10mg (co-lyophilized in single vial) |
| Total Peptide Mass | 80mg per vial |
| Component Categories | ECM/collagen (GHK-Cu) + Melanocortin anti-inflammatory (KPV) + Tissue repair/angiogenesis (BPC-157) + Actin/cell migration (TB-500) |
| Primary Research Applications | Combined anti-inflammatory + tissue repair biology; multi-pathway repair cascade research; blend vs. individual component comparison studies |
| Related Individual Guides | GHK-Cu (YPB.221/222) • KPV • BPC-157 (YPB.212/213) • TB-500 (YPB.214/215) |
| Research Comparison | GLOW Blend (YPB.218; GHK-Cu + BPC-157 + TB-500 triple) + KLOW adds KPV for melanocortin anti-inflammatory pathway; Wolverine Blend (YPB.216/217; BPC-157 + TB-500 dual) |
| FDA Status | Not research-grade. Research Use Only (RUO). |
| WADA Status | Component-dependent: TB-500 variants subject to WADA monitoring; no single Prohibited List classification as a blend. Individual component WADA status applies. |
| Storage | Lyophilized: −20°C. Reconstituted: sterile bacteriostatic water; 2–8°C, use within 28 days. Co-lyophilized blends generally stable under same conditions as individual components. |
The Four Pathways: Why Each Component Is Non-Redundant
Layer 1 — ECM Remodeling: GHK-Cu
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex; MW ~340 Da) is the most concentrated component in the KLOW Blend at 50mg. It represents the extracellular matrix (ECM) remodeling layer of the blend: GHK-Cu activates TGF-β1/SMAD3 signaling to upregulate collagen type I, III, IV, and V synthesis; stimulates VEGF and EGF receptor pathways to promote angiogenesis and epidermal regeneration; chelates copper to deliver it to SOD (superoxide dismutase) and catalase enzyme cofactor sites, amplifying antioxidant defense at the repair site; and activates the matrix metalloproteinase (MMP) system for controlled ECM remodeling (both MMP induction for clearing damaged matrix and TIMP upregulation for controlling excessive degradation). GHK-Cu at 50mg represents the highest per-component dose in the blend, reflecting the well-established safety margin of copper tripeptides in research models and the need for adequate concentration at ECM interface.
Layer 2 — Melanocortin Anti-Inflammation: KPV
KPV (Lys-Pro-Val; MW ~372 Da) is the alpha-MSH C-terminal tripeptide fragment — the smallest but pharmacologically active anti-inflammatory fragment of the melanocortin system. It activates MC1R and MC3R to suppress NF-κB nuclear translocation, reducing transcription of TNF-α, IL-1β, IL-6, and COX-2 at the site of inflammation. This melanocortin anti-inflammatory pathway is mechanistically orthogonal to GHK-Cu’s ECM effects: KPV damps the cytokine storm that would otherwise perpetuate the inflammatory microenvironment, allowing the repair signals from GHK-Cu, BPC-157, and TB-500 to operate without constant pro-inflammatory interference. KPV is particularly relevant in gut and skin models where MC1R/MC3R expression is high.
Layer 3 — Vascular and Growth Factor Repair: BPC-157
BPC-157 (body protection compound; 15 AA; stable gastric pentadecapeptide fragment) activates FAK (focal adhesion kinase) and paxillin signaling in fibroblasts and endothelial cells → VEGF upregulation → angiogenesis and capillary formation; activates NO (nitric oxide) synthase for vasodilation at the repair site; and upregulates EGR1 (early growth response protein 1) → PDGF-B, FGF, and tendon growth factors. The vascular and growth factor layer addressed by BPC-157 is distinct from GHK-Cu’s ECM remodeling and KPV’s cytokine suppression: BPC-157 specifically drives capillary ingrowth and growth factor gradient establishment that are prerequisites for tissue regeneration.
Layer 4 — Cell Migration and Actin Dynamics: TB-500
TB-500 (synthetic thymosin β4 analog; 43 AA) binds G-actin (unpolymerized actin monomers) via its central LXXLL motif, sequestering actin to modulate local actin polymerization dynamics → promotes lamellipodia formation and directional cell migration of fibroblasts, keratinocytes, and endothelial cells toward wound sites. TB-500 also has independent anti-inflammatory effects (NF-κB modulation; thymosins have intrinsic immune-modulatory properties) that complement KPV’s melanocortin-mediated anti-inflammatory activity. The cellular migration layer addressed by TB-500 is required for physical wound closure and tissue reconstitution after the inflammatory environment has been controlled (KPV), ECM has been prepared (GHK-Cu), and vascular supply has been established (BPC-157).
Research Applications and Tissue Models
Inflammatory Bowel Disease and Gut Mucosal Research
The KPV component has the strongest published evidence base in gut inflammation models, where MC1R/MC3R receptor expression on intestinal epithelial cells and lamina propria macrophages mediates direct anti-inflammatory signaling. BPC-157 has published data in TNBS colitis and acetic acid colitis models with mucosal protection and healing. GHK-Cu supports mucosal ECM reconstitution. TB-500’s cell migration activity is relevant for re-epithelialization of denuded intestinal mucosa. The KLOW Blend provides all four pathways simultaneously for IBD-model gut research.
Dermal and Skin Repair Research
GHK-Cu is the most extensively published peptide in dermal repair research: collagen synthesis, wound contraction, re-epithelialization. TB-500 provides the keratinocyte and fibroblast migration signal. KPV addresses the skin-specific melanocortin inflammatory pathway. BPC-157 provides the angiogenic component for dermal vascular repair. The KLOW Blend closely mirrors the biology of full-thickness wound healing at the molecular level, making it a natural tool for skin model research.
Tendon, Ligament, and Connective Tissue Research
BPC-157 has the most specific published tendon/ligament repair data among the four components (FAK-paxillin activation in tenocytes; tendon growth factor upregulation in published rotator cuff and Achilles tendon models). TB-500 provides tenocyte migration. GHK-Cu promotes collagen synthesis for structural repair. KPV reduces inflammatory destruction of peritendinous tissue. Together these provide multi-pathway coverage of tendon/connective tissue repair biology.
KLOW vs. Other YPB Blend Research Options
| Parameter | KLOW Blend (YPB.264) | GLOW Blend (YPB.218) | Wolverine Blend (YPB.217) |
|---|---|---|---|
| Components | GHK-Cu (50mg) + KPV (10mg) + BPC-157 (10mg) + TB-500 (10mg) | GHK-Cu + BPC-157 + TB-500 | BPC-157 (10mg) + TB-500 (10mg) |
| Unique to KLOW | KPV (melanocortin MC1R/MC3R NF-κB suppression; gut/skin anti-inflammatory) | — | — |
| Primary Research Focus | Full-spectrum anti-inflammatory + repair: ECM (GHK-Cu) + melanocortin anti-inflammation (KPV) + vascular/growth factor (BPC-157) + cell migration (TB-500) | Skin-oriented ECM repair + angiogenesis + cell migration; no melanocortin pathway | Core tissue repair duo; no ECM remodeling layer; no melanocortin layer |
| Best for | IBD/gut, dermal, and complex multi-tissue repair models where inflammation control + repair are both required simultaneously | Skin/dermal research; aesthetic/collagen biology | Acute injury repair models; tendon/ligament focus; simpler study designs |
| Individual guides | 4 component guides linked above | GLOW guide; 3 component guides | Wolverine guide; 2 component guides |
Market Demand and Research Interest
| Demand Indicator | KLOW Blend Data Point |
|---|---|
| Research rationale | Four mechanistically distinct but complementary repair pathways in single vial; covers ECM, melanocortin, vascular/growth factor, and cytoskeletal layers simultaneously |
| Convenience value | Single vial, single reconstitution, single COA for four-compound combination; simplifies multi-compound research procurement |
| Unique catalog position | Most comprehensive peptide blend in YPB catalog; only blend including melanocortin pathway (KPV); expands on GLOW Blend by adding dedicated anti-inflammatory layer |
| White-label value | High perceived value from the combination; supports premium catalog positioning; individual component value exceeds $300 at MSRP |
| Keyword difficulty range | Very low (KD <3); emerging blend category; first-mover advantage |
How Can Researchers Offer KLOW Blend Under Their Own Brand?
Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP |
|---|---|---|---|---|
| YPB.264 | KLOW Blend (GHK-Cu 50mg + KPV 10mg + BPC-157 10mg + TB-500 10mg) | TBC Premier | TBC Core | TBC |
Contact the YPB team for confirmed Premier and Core pricing. Use the YPB Profit Calculator to model projected revenue. The KLOW Blend’s four-component composition — covering ECM, melanocortin, vascular, and cytoskeletal repair pathways — positions it as the most complete tissue repair research blend in the YPB catalog. Combined with the Wolverine Blend (YPB.217; BPC-157 + TB-500) and GLOW Blend (YPB.218; GHK-Cu + BPC-157 + TB-500), white-label brands can offer a complete repair blend progression: dual (Wolverine) → triple (GLOW) → quad-pathway (KLOW). Download the full catalog for all blend category pricing.
Methodology & Data Sources
Individual component literature: PubMed searched for “GHK-Cu,” “KPV alpha-MSH,” “BPC-157,” and “thymosin beta-4 TB-500.” Search conducted through April 2026. For component-specific references, see the individual research guides linked above.
Limitations: Published research on the specific KLOW four-component blend combination is limited as of April 2026; research characterizing the full blend as a co-used preparation is not yet published. The research value propositions presented reflect the published individual component literatures and their mechanistic complementarity. Whether the four components produce additive or synergistic effects when co-used requires original research using the blend vs. individual component controls. This article is for educational purposes only.
References
- Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci, 19(7), 1987. (GHK-Cu comprehensive mechanism.)
- Dalmasso, G., et al. (2008). The peptide KPV inhibits NF-κB-mediated pro-inflammatory signaling. J Pediatr Gastroenterol Nutr. (KPV MC1R/NF-κB mechanism.)
- Chang, C. H., et al. (2011). BPC 157 augments tendon-to-bone healing. J Appl Physiol. (BPC-157 FAK-paxillin tendon data.)
- Goldstein, A. L., & Kleinman, H. K. (2015). Actobind, thymosin β4, and healing. Ann N Y Acad Sci. (TB-500/thymosin β4 actin/migration mechanism.)
- See individual component guides for comprehensive component-specific references: GHK-Cu, KPV, BPC-157, TB-500.
Frequently Asked Questions
The KLOW Blend (YPB.264) is a four-component research peptide combination: GHK-Cu (50mg; copper tripeptide; ECM remodeling, collagen synthesis, antioxidant), KPV (10mg; Lys-Pro-Val; α-MSH C-terminal fragment; MC1R/MC3R anti-inflammatory NF-κB suppression), BPC-157 (10mg; 15-AA stable gastric pentadecapeptide; FAK-paxillin/VEGF/angiogenesis), and TB-500 (10mg; 43-AA thymosin β4 analog; G-actin binding/cell migration). Each component addresses a mechanistically distinct layer of the inflammatory and tissue repair cascade: ECM (GHK-Cu), melanocortin immune signaling (KPV), vascular/growth factor (BPC-157), cytoskeletal/migration (TB-500). Co-lyophilized in a single vial for research convenience. For the complete mechanism of each component, see the individual research guides. Research Use Only (RUO). Updated April 2026.
The GLOW Blend (YPB.218) contains GHK-Cu + BPC-157 + TB-500 — the ECM remodeling, vascular/growth factor, and cell migration layers. It does not address the cytokine/inflammatory signaling layer directly. KPV is the α-MSH C-terminal tripeptide (Lys-Pro-Val) that activates MC1R and MC3R melanocortin receptors to directly suppress NF-κB and reduce pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6). The KLOW Blend adds KPV to the GLOW formulation specifically to address this fourth layer: if a repair environment is dominated by active NF-κB-driven inflammation, the repair signals from GHK-Cu, BPC-157, and TB-500 may be insufficient to overcome the inflammatory microenvironment. KPV’s NF-κB suppression helps establish the anti-inflammatory conditions under which the three repair-promoting peptides can operate most effectively. KLOW is therefore most appropriate for research models where significant active inflammation is a feature of the model (IBD, inflammatory arthritis, acute injury), while GLOW may be sufficient for repair models where inflammation has already partially resolved and ECM/vascular repair is the primary remaining need.
The 50mg GHK-Cu vs. 10mg for each of the other components reflects both the published effective concentration ranges for each peptide and the cost economics of the blend. GHK-Cu is among the most affordable peptides in the catalog (YPB.221: Premier $23.22; MSRP $80 for 50mg — relatively low cost per mg compared to synthetic peptides like BPC-157 or TB-500), allowing higher inclusion mass without proportionally increasing blend cost. GHK-Cu also has a broader effective concentration range in research models: published data shows GHK-Cu activity from nanomolar (receptor binding) to micromolar/millimolar concentrations (ECM effects), with higher concentrations producing greater collagen synthesis induction in fibroblast models. The 10mg doses for BPC-157, TB-500, and KPV reflect the typical single-vial sizes in which these compounds are commonly sold and studied individually in the catalog, and at which published research documents activity. For researchers who want different component ratios, all four compounds are available individually to design custom concentration combinations.
As of April 2026, there is no published peer-reviewed research specifically on the KLOW four-component blend as a co-formulated preparation. The research rationale for the blend is based on the published individual component literatures and their mechanistic complementarity — each component is individually characterized across multiple published studies, and their mechanisms address non-overlapping pathways in the repair cascade. Whether co-administration produces additive, synergistic, or antagonistic interactions is an open research question that represents the primary scientific value of studying the KLOW Blend experimentally: using the blend vs. individual components in controlled cell culture and in vivo models to characterize interaction type. All four individual components have independent published literature; see the linked individual research guides for the component-specific evidence bases. The blend article does not claim published combined-formulation data; it positions the blend as a research tool for generating this data.
Yes. YourPeptideBrand.com provides white-label dropship for KLOW Blend as YPB.264 (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with four-layer mechanism descriptions, component composition table, GLOW/Wolverine/KLOW blend comparison, and COA library links. Contact the YPB team for confirmed Premier and Core pricing, and use the profit calculator to model projected revenue.
Every KLOW Blend batch includes a lot-specific COA that confirms each component: HPLC purity for the overall blend (≥95%); identity confirmation for GHK-Cu (MS at ~340 Da for the copper complex), KPV (MS at ~372 Da), BPC-157 (MS at ~1,419 Da), and TB-500 (MS at ~4,964 Da for the synthetic analog); endotoxin (<1 EU/mg); TAMC; and TYMC. The blend COA confirms all four component masses match specifications. All lots are traceable through the batch-specific COA library.
Position the three blends as a progression by research complexity: Wolverine Blend (BPC-157 + TB-500) = the dual-component core repair toolkit for acute injury models; GLOW Blend (GHK-Cu + BPC-157 + TB-500) = the triple-layer repair blend adding ECM remodeling/collagen synthesis; KLOW Blend (GHK-Cu + KPV + BPC-157 + TB-500) = the most complete quad-pathway combination adding dedicated melanocortin NF-κB anti-inflammatory suppression for research models where active inflammation is a key feature. Research buyers naturally move up the blend complexity tier as their models require broader pathway coverage. KLOW is the top tier — the “complete toolkit” positioning. Individual components should also be available for researchers who need single-compound reference arms to study KLOW blend interactions.
KLOW Blend is most appropriate for research models that feature concurrent active inflammation AND tissue repair requirements — where addressing only one dimension would be insufficient. The best-suited models include: (1) IBD/gut mucosal research: KPV has strong published gut anti-inflammatory data; BPC-157 has published GI mucosal healing data; GHK-Cu and TB-500 provide ECM and migration support; (2) Inflammatory dermal wound models: all four components have dermal/skin relevance; KPV is particularly active in skin MC1R; GHK-Cu has the deepest dermal ECM/collagen literature; (3) Joint/synovial inflammation research: KPV NF-κB suppression reduces inflammatory joint damage while GHK-Cu/BPC-157/TB-500 support connective tissue repair; (4) Tendon/ligament repair in inflammatory context: BPC-157 tendon data + TB-500 tenocyte migration + KPV acute inflammation control + GHK-Cu collagen synthesis. Models where inflammation has already resolved and only repair is needed may be better served by GLOW or Wolverine to avoid unnecessary complexity in the experimental design.
Key Takeaways
Research Takeaways
- Four non-overlapping pathways: ECM (GHK-Cu/TGF-β1/collagen) + melanocortin anti-inflammation (KPV/MC1R-3R/NF-κB) + vascular/growth factor (BPC-157/FAK-paxillin/VEGF) + cytoskeletal migration (TB-500/G-actin/LXXLL).
- GHK-Cu 50mg: Highest concentration; ECM and collagen layer; copper delivery; affordable per-mg cost enables dominant loading.
- KPV is KLOW’s unique addition vs. GLOW: Melanocortin NF-κB anti-inflammatory suppression; gut/skin MC1R/MC3R; creates anti-inflammatory environment enabling repair.
- Additive vs. synergistic interaction unknown: No published combined-formulation research as of April 2026; researching blend vs. individual components is the primary scientific value.
- Best for active inflammation + repair models: IBD, inflammatory dermal wounds, joint research, tendon repair in inflammatory context.
Business Takeaways
- Most comprehensive YPB peptide blend — four pathway coverage; only blend including KPV melanocortin pathway.
- Wolverine (2) → GLOW (3) → KLOW (4) blend progression = natural catalog upgrade path.
- Individual components available separately for single-compound reference arm study designs.
- Contact YPB for confirmed pricing on YPB.264.
Ready to add KLOW Blend to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”klow-blend”]